

# Dostarlimab : A Step Against Cancer

Alisha H. Mujawar<sup>1</sup>, Sachin S. Navale<sup>2</sup>, Nilofer S. Sayyad<sup>2</sup>, Shrutika R. Kadam<sup>2</sup>,  
Rushikesh M. Sankpal<sup>2</sup>, Punam D. Mali<sup>2</sup>

Student, Department of Pharmaceutics<sup>1</sup>

Assistant Professor, Department of Pharmaceutics<sup>2</sup>

Nootan College of Pharmacy, Kavathe Mahankal, Sangli, Maharashtra, India

**Abstract:** Immunotherapy have become the backbone in the treatment of cancer recently. Immune checkpoint inhibitors checkpoint therapy, monoclonal antibody therapy and chimeric antigen T-cell therapy have shown the peak level exceptional properties that activate the immune system to response to cancer cells, inhibiting their progression. Immune checkpoint inhibitors have demonstrated significant clinical activity across various types of tumor. Nowadays dostarlimab a new drug have been showing a miracle in the treatment of rectal cancer. In Year 2022 June, the clinical trial NCT04165772 reported a 100% remission rate for rectal cancer. This clinical trial have proved that they can match a tumor and the genetics of what is driving it, with therapy. Dostarlimabis approved on August 17,2021 by the U.S Food and Drug Administration (FDA) which treat mismatch repair deficient (dMMR) advanced-stage breast cancer Dostarlimab is a humanized monoclonal antibody that works by binding with high affinity to PD-1 resulting in inhibition of binding to PD-L1 and PD-L2. Research is done on the study of effect of dostarlimab on various patients.

**Keywords:** Dostarlimab, Endometrial Carcinoma, PD-1 Inhibitor, Immunotherapy, Cancer Therapy

## REFERENCES

- [1]. Barbara costa and Nuno vale Dostarlimab: A review
- [2]. Kumar S., Sharma G., Wang Z., Marino M.H., Neben T.Y., Lu S., Luo
- [3]. S., Ghosh S., Roberts S., Kehry M.R, et al. Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1
- [4]. Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal.
- [5]. A Markham drugs, 2021 Dostarlimab: first approval
- [6]. L. Kesherman, s Ahrari, s kheureux – Future oncology, 2021 Dostarlimab in treatment of recurrent or primary advanced endometrial cancer.
- [7]. A.oaknin, AV Tinker, L Gilbert, V samouelian – JAMA 2020 Clinical activity and safety of anti-programmed death-1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair deficient.
- [8]. A.oaknin, AV Tinker, L Gilbert, V samouelian – JAMA 2021 Clinical activity and safety of anti-programmed death-1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair deficient – endometrial cancer.
- [9]. V singh, A sheikh, MAS Abourehab, P.kesharwani – biosensor 2022, Dostarlimab as a miracle drug: rising hope against cancer treatment.
- [10]. P saha, A Kumar, J Bhanja, R Shaik, Akash limba Kawale, Roshan Kumar International Journal for Research in Applied Science and Biotechnology, A Review on immune blockade safety and antitumor Activity of Dostarlimab Therapy in Endometrial cancer.
- [11]. J Rubio perez, R Hernandez, T Hernandez, Bernard Doger, V casado, V Moreno. Drugs of today (Barcelona, Spain: 1998) 57 (3),
- [12]. 187-197, 2021 Dostarlimab for the treatment of endometrium cancer and other solid tumors.
- [13]. S Dioun, L Chen, A Melamed, A Gockley, Caryn M St. Clair, June Y, Hou, Fady Khoury – Colladino, Chin Hur, Elena Elkin, Melissa Accordino, Dawn L Hershman, Jason D Wright, Dostarlimab for recurrent mismatch repair deficient Endometrial Cancer: A cost Effectiveness study.

- [14]. A Madariaga, S Garg, N Tchakian, NC Dhani, Waldo Jimenez, Josee – Lyne Ethier, Lucy Gilbert, Angela Rodriguez, Lucy Chan, phase II trial assessing niraparib with or without Dostarlimab (Anti-PD-1) in recurrent Endometrial carcinoma.
- [15]. Ui Beom Park, Tae Jun Jeong, Nahyeon Gu, Hyun Tae Lee, Yong-seok Heo. Molecular basis of PD-1 blockade by Dostarlimab, the FDA- approved antibody for cancer Immunotherapy.